Hyperhomocysteine: a key mediator linking chronic kidney disease to parkinson’s disease

Clicks: 20
ID: 329812
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #119 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Chronic kidney disease affects more than 10% of the global population and is associated with elevated Parkinson’s disease risk, substantially compromising patients’ quality of life. However, the precise pathophysiological mechanisms underlying this association remain unclear. This review aims to synthesize current evidence and explore the potential pathophysiological mechanisms linking chronic kidney disease to the pathogenesis of Parkinson’s disease. Main Body Hyperhomocysteinemia, characterized by elevated homocysteine levels, is a common metabolic disturbance in both chronic kidney disease and Parkinson’s disease. In CKD, impaired renal clearance and metabolic dysfunction lead to homocysteine accumulation. This review examines the hypothesis that hyperhomocysteinemia serves as a key biochemical mediator, linking the two diseases by driving neurodegenerative processes central to Parkinson’s disease pathogenesis, including oxidative stress, chronic neuroinflammation, and neuronal apoptosis, which culminate in dopaminergic neurodegeneration. Conclusions This review delineates the pathogenic pathways linking CKD to Parkinson’s disease through hyperhomocysteinemia, positioning it as a plausible and actionable intermediary. Addressing hyperhomocysteinemia has emerged as a rational strategy with the potential to elucidate disease mechanisms and mitigate Parkinson’s disease risk in the vulnerable chronic kidney disease population.
Reference Key
openalex_W7214404556 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Huiqi Chen, Sijin Li, Zhengzhipeng Zhang, Yuning Liu, Jin Tang Yang, Pengyuan Chen, Pei Luo, Li Yin, Hui Huang
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag329
URL
https://doi.org/10.1093/ckj/sfag329
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.